Thrombin Receptor Polymorphisms and Stroke Outcomes with Clopidogrel

Response to dual antiplatelet treatment varies according to thrombin receptor genotype.

Dual antiplatelet therapy with aspirin and clopidogrel (A+C) has been demonstrated to reduce the risk for short-term (90-day) stroke in patients who present with a minor stroke or transient ischemic attack. Clopidogrel has variable efficacy according to CYP2C19 genotype. These authors have investigated a different genetic aspect, namely polymorphisms in the gene for protease activated receptor 1 (PAR-1). PAR-1 is a major thrombin receptor and mediates platelet activation. The authors investigated three variations in the PAR-1 F2R gene (AT, TT, and AA) and rates of stroke, overall vascular events, and bleeding in patients treated with A+C versus aspirin alone. Participants in China were genotyped for the PAR-1 F2R gene; 29.4% were AA homozyg…

Reviewing Author

Seemant Chaturvedi, MD

Disclosures

Consultant/Advisory BoardBayer Pharmaceuticals; Novartis

Grant/Research SupportNational Institute of Neurological Disorders and Stroke

Editorial BoardsNeurology; Stroke

Seemant Chaturvedi, MD

Disclosures

Consultant/Advisory BoardBayer Pharmaceuticals; Novartis

Grant/Research SupportNational Institute of Neurological Disorders and Stroke

Editorial BoardsNeurology; Stroke

Thrombin Receptor Polymorphisms and Stroke Outcomes with Clopidogrel

Topics

Reviewing Author